Compugen Historical Income Statement
CGEN Stock | USD 1.61 0.09 5.92% |
Historical analysis of Compugen income statement accounts such as Interest Expense of 29.4 K, Selling General Administrative of 6.6 M or Total Revenue of 35.1 M can show how well Compugen performed in making a profits. Evaluating Compugen income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Compugen's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Compugen latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Compugen is a good buy for the upcoming year.
Compugen |
About Compugen Income Statement Analysis
Compugen Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Compugen shareholders. The income statement also shows Compugen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Compugen Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Compugen. It is also known as Compugen overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Compugen income statement and is an important metric when analyzing Compugen profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Compugen's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Compugen current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.At this time, Compugen's Net Interest Income is very stable compared to the past year. As of the 28th of November 2024, Reconciled Depreciation is likely to grow to about 698.3 K, while Depreciation And Amortization is likely to drop about 452.2 K.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 871K | 1.7M | 3.2M | 3.4M | Interest Income | 894K | 1.7M | 3.0M | 3.1M |
Compugen income statement Correlations
Click cells to compare fundamentals
Compugen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Compugen income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 989K | 715K | 461K | 482K | 476K | 452.2K | |
Interest Expense | 1.8M | 1.7M | 869K | 27K | 31K | 29.5K | |
Selling General Administrative | 8.4M | 9.8M | 10.9M | 10.3M | 9.7M | 6.6M | |
Gross Profit | (989K) | 1.9M | 5.3M | 6.5M | 31.5M | 33.0M | |
Other Operating Expenses | 28.9M | 33.5M | 41.1M | 42.9M | 46.5M | 26.9M | |
Operating Income | (28.9M) | (31.5M) | (35.1M) | (35.4M) | (13.0M) | (13.6M) | |
Ebit | (28.9M) | (31.5M) | (35.1M) | (35.4M) | (13.0M) | (13.6M) | |
Research Development | 19.8M | 22.8M | 28.7M | 30.6M | 34.5M | 17.9M | |
Ebitda | (27.9M) | (30.8M) | (34.6M) | (34.9M) | (12.5M) | (13.1M) | |
Cost Of Revenue | 989K | 60K | 680K | 975K | 2.0M | 1.4M | |
Total Operating Expenses | 28.9M | 33.4M | 40.4M | 41.9M | 44.0M | 25.9M | |
Income Before Tax | (28.1M) | (29.7M) | (34.2M) | (33.6M) | (9.8M) | (10.3M) | |
Total Other Income Expense Net | 820K | 1.8M | 871K | 1.7M | 3.2M | 3.4M | |
Net Income | (27.3M) | (27.3M) | (32.9M) | (33.7M) | (18.8M) | (19.7M) | |
Income Tax Expense | (722K) | (2.4M) | (1.3M) | 58K | 9.0M | 9.4M | |
Selling And Marketing Expenses | 651K | 871K | 842K | 932K | 244K | 231.8K | |
Net Income From Continuing Ops | (27.3M) | (29.7M) | (34.2M) | (33.7M) | (18.8M) | (19.7M) | |
Net Income Applicable To Common Shares | (27.3M) | (29.7M) | (34.2M) | (33.7M) | (30.3M) | (31.8M) | |
Interest Income | 935K | 1.8M | 894K | 1.7M | 3.0M | 3.1M | |
Net Interest Income | 903K | 1.7M | 871K | 1.7M | 3.2M | 3.4M | |
Reconciled Depreciation | 989K | 715K | 461K | 482K | 476K | 698.3K |
Pair Trading with Compugen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.Moving together with Compugen Stock
Moving against Compugen Stock
0.84 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.77 | ESPR | Esperion Therapeutics | PairCorr |
0.69 | GILD | Gilead Sciences | PairCorr |
0.66 | DRUG | Bright Minds Biosciences | PairCorr |
0.62 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.03 | Revenue Per Share 0.48 | Quarterly Revenue Growth 3.461 | Return On Assets (0.03) | Return On Equity (0.16) |
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.